Prognostic factors and efficacy of human intravenous immunoglobulin G in dogs with idiopathic immune-mediated hemolytic anemia: a retrospective study.
10.14405/kjvr.2016.56.3.139
- Author:
So Young PARK
1
;
Hakhyun KIM
;
Byeong Taek KANG
;
Ji Houn KANG
;
Mhan Pyo YANG
Author Information
1. College of Veterinary Medicine and Veterinary Medical Center, Chungbuk National University, Cheongju 28644, Korea. jhkang@chungbuk.ac.kr mpyang@chungbuk.ac.kr
- Publication Type:Original Article
- Keywords:
autoimmune hemolytic anemia;
canine;
hemoglobinuria;
mortality;
seasonality
- MeSH:
Anemia, Hemolytic*;
Anemia, Hemolytic, Autoimmune;
Animals;
Dogs*;
Hemoglobinuria;
Hospitalization;
Humans*;
Immunoglobulin G*;
Immunoglobulins*;
Mortality;
Retrospective Studies*
- From:Korean Journal of Veterinary Research
2016;56(3):139-145
- CountryRepublic of Korea
- Language:English
-
Abstract:
This study was conducted to determine the effect of treatment with intravenous human immunoglobulin G (hIVIgG) on outcome in dogs with idiopathic immune-mediated hemolytic anemia (IMHA), and to identify prognostic variables that determine outcome in affected dogs. Thirty-seven dogs that met the inclusion criteria were enrolled in a retrospective study. The dogs were categorized into two groups based on their having received hIVIgG. There was no significant difference in survival between the hIVIgG group and the non-hIVIgG group. Mortality during hospitalization and at 1 month, 1 year, or 2 years after discharge was not significantly different between the hIVIgG and the non-hIVIgG groups. Hemoglobinuria was significantly less prevalent in dogs that lived more than 1 year than in those who lived less than 1 year, and was less prevalent in dogs that lived more than 2 years than in those who lived less than 2 years. However, there was no difference in the presence of hemoglobinuria between dogs that lived less than 1 month and those that lived more than 1 month. Overall, there was no evidence of a beneficial effect of hIVIgG in dogs with idiopathic IMHA.
